Yahoo
NYSE - Delayed Quote USD

Danaher Corporation (DHR)

230.25 +3.91 (+1.73%)
At close: November 6 at 4:02:24 PM EST
230.25 0.00 (0.00%)
After hours: November 6 at 5:59:09 PM EST
Trade Danaher on Coinbase
Chart Range Bar
Loading chart for DHR

What's happening with DHR?

28m ago
Powered by Yahoo Scout

Danaher’s recent coverage centers on FDA-cleared diagnostic assays, improving bioprocessing trends, and a recovery in life-sciences demand. Analysts raised targets toward $250–$275, while valuation remains sensitive to respiratory weakness, China pricing pressure, and execution. The company’s most recent completed trading session gained 1.73% on November 6, including regular-session and after-hours trading.

Powered by Yahoo Scout
  • Previous Close 226.34
  • Open 222.96
  • Bid 222.50 x 20000
  • Ask 232.88 x 10000
  • Day's Range 222.96 - 230.53
  • 52 Week Range 160.93 - 242.80
  • Volume 3,737,251
  • Avg. Volume 3,990,254
  • Market Cap (intraday) 161.988B
  • Beta (5Y Monthly) 0.80
  • PE Ratio (TTM) 38.12
  • EPS (TTM) 6.04
  • Earnings Date (est.) Jan 27, 2027
  • Forward Dividend & Yield 1.60 (0.69%)
  • 1y Target Est 259.90
  • Morningstar Rating Rating available with Stock Picks access

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

www.danaher.com

58,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DHR
1.18%
S&P 500 (^GSPC)
7.76%

1-Year Return

DHR
10.10%
S&P 500 (^GSPC)
9.77%

3-Year Return

DHR
19.85%
S&P 500 (^GSPC)
68.96%

5-Year Return

DHR
8.78%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 6.55B
Earnings 1.24B
Profit Margin 18.84%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
2B
4B
6B
14.0%
15.0%
16.0%
17.0%
18.0%

Analyst Insights

View More

Analyst Price Targets

220.00
259.90 Average
230.25 Current
310.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/22/2026
Analyst Citigroup
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 230 -> 270

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    16.91%

  • Return on Assets (ttm)

    4.06%

  • Return on Equity (ttm)

    8.19%

  • Revenue (ttm)

    25.61B

  • Net Income Avi to Common (ttm)

    4.29B

  • Diluted EPS (ttm)

    6.04

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.68B

  • Total Debt/Equity (mrq)

    51.80%

  • Levered Free Cash Flow (ttm)

    4.75B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: